You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三生國健(688336.SH):SSGJ-706注射液開展晚期實體瘤、復發/難治淋巴瘤的臨牀試驗獲批
格隆匯 12-27 16:52

格隆匯12月27日丨三生國健(688336.SH)公佈,近日,公司收到國家藥品監督管理局(“國家藥監局”)核准簽發的《藥物臨牀試驗批准通知書》批准公司特異性抗體注射液SSGJ-706開展在晚期實體瘤、復發/難治淋巴瘤受試者中評估SSGJ-706的安全性、耐受性、藥代動力學和初步療效的開放性、多中心、I/II 期研究公司將在近期開展相關臨牀試驗。

目前抗 PD1 單抗/ PDL1 單抗的單藥及聯合化療在多個腫瘤領域中均表現出比既往標準治療優異的療效。然而,PD1/PDL1 抑制劑單藥治療在部分晚期實體瘤患者中治療反應率低或需要在 PDL1 高表達人羣中才能獲得更好的治療效果,這使能夠從 PD1/PDL1 抑制劑單藥治療中獲益的人羣有限。為進一步加強免疫治療的功效,雙免疫檢查點抑制劑聯合治療等多種療法不斷出現,研究表明,同時靶向兩種不同靶點的雙抗類抑制劑治療效果良好且相比於兩個單抗聯合用藥的不良反應發生率可能較低。

SSGJ-706 是三生國健利用自主知識產權雙特異抗體平台開發的一種重組雙特異抗體,可同時結合兩個和腫瘤免疫抑制功能密切相關的靶點,從而更有效地促進 T 細胞活化和增殖,進一步增強其腫瘤殺傷活性。其藥效學研究證實了 SSGJ-706 在多種移植瘤中的抗腫瘤療效。此外,非臨牀研究數據提示 SSGJ-706 有良好的安全性和耐受性。SSGJ-706 的開發有望使更多的腫瘤患者從創新免疫療法中獲益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account